Neumora Therapeutics (NASDAQ:NMRA) Posts Quarterly Earnings Results, Meets Estimates

Neumora Therapeutics (NASDAQ:NMRA) released its quarterly earnings results on Tuesday. The company reported ($0.34) EPS for the quarter, meeting the consensus estimate of ($0.34), Briefing.com reports.

Neumora Therapeutics Stock Down 5.7 %

Shares of NASDAQ:NMRA traded down $0.56 during trading on Friday, hitting $9.21. 39,471 shares of the company’s stock were exchanged, compared to its average volume of 475,355. The firm has a 50-day moving average price of $13.00 and a two-hundred day moving average price of $14.01. Neumora Therapeutics has a 1-year low of $8.82 and a 1-year high of $21.00.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Neumora Therapeutics from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Monday, March 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Neumora Therapeutics in a report on Thursday, March 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a report on Friday, April 12th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.57.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.